HeartBeam Wins the FDA Argument and Loses the Commercial One
A 510(k) pathway, Breakthrough designation and pivotal data landed in a quarter where the concierge-subscription story quietly vanished — and the stock fell 35% into a December delisting deadline.
BEAT · Earnings Call · 2026-11-12
Two Companies, One Ticker
HeartBeam entered Q3 as a company selling a $750-a-year cardiac subscription into high-end concierge practices in two coastal geographies. It exited Q3 as a company selling an FDA argument. Those are different businesses, with different investors, and the tape has already voted on which one it thinks is being funded. The share price sits roughly 40% below its mid-July high of $0.66 and down about 35% over the last ninety trading days, per the price tape; from the 2022 peak of $5.94 it is a 93% drawdown. Nothing in the quarter's clinical news explains that. What explains it is the other half of the call.The Milestones Are Real
On the regulatory side, management delivered more in 90 days than it had in the prior year. The FDA agreed to a heart attack assessment 510(k) rather than a De Novo — a materially shorter road — on top of Breakthrough Device Designation and admission to the TAP program, which is what gets a small company into a room with CMS and payers early. The ALIGN-ACS readout at TCT 2026 was the substance behind it: 132 emergency-department patients in Belgrade, where the patient-recorded device matched the standard 12 lead ECG. “HeartBeam showed higher specificity at 81.8% compared with 71.4% for the standard 12-lead ECG, with comparable sensitivity of 60.2% compared with 63.0%.” — Branislav Vajdic, Chief Medical Officer · 2026-11-12 Equal area under the curve, better reader agreement (Fleiss' kappa 0.73 versus 0.54), and every patient able to capture a recording unaided. Add HEADSTART-ACS in Indonesia — 486 patients enrolled ahead of schedule, more than 600 patients of cumulative clinical evidence — and the U.S. pivotal trial design is now a scaled-up ALIGN-ACS: roughly 300 patients, 8–10 centers, first enrollment plausibly before year-end, completion mid-2027. Finalizing the pivotal study design this quarter is the next hard checkpoint.What Management Stopped Saying
Now the part that matters more. For four straight calls, HeartBeam's commercial narrative was the concierge channel: anchor accounts, flagship account depth, Southern California and South Florida territories, and a breakeven math built on patient counts. In August, the CFO was explicit about it being the near-term scorecard: “We want to get through Q3 and really start to see the orders come in and roll this out to start to provide those metrics... we've told the market historically it's about 30,000 patients to get to break even or it's cash flow positive.” — Tim Cruickshank, CFO · 2026-08-13 Q3 came. The orders metric did not. The Chief Commercial Officer who owned that plan is absent from this call entirely, the CEO who framed the strategy has been replaced in the seat by Executive Chairman Richard Ferrari, and the founder has been re-titled Chief Medical Officer. The keyword record confirms the deletion rather than a mere de-emphasis: concierge practice, Southern California and South Florida all register as this quarter's sharpest decliners in the company's own momentum history, while TAP program and heart attack assessment spike to the top. That is a management team changing the subject, and the keywords caught it. Asked directly whether the already-cleared arrhythmia product could be monetized, Ferrari did not spin:That is an honest answer and a strategically enormous one. It converts HeartBeam from a company with a small but growing revenue line into a pure regulatory binary.Our focus, as you've heard us say before, with the arrhythmia detection right now, monetizing it in a large way is -- just simply isn't the focus... revenue generated from commercialization is just being modest, and we're testing the market and trying to understand reimbursement.